GlassScriptPhysician profile
Devyn Alexandria Glover
NPI 1548829567
$2,537.52
in general payments reported to CMS, 2019-2025
12 companies · $1,305 in 2025
The $1,305 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $121 · 2023: $375 · 2024: $735 · 2025: $1,305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,416.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $688.93 | 2023-2025 | Idosetr, Istent Infinite, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Bausch & Lomb Americas INC. | $382.28 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $364.84 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $252.94 | 2024-2025 | Simbrinza, Clareon, Tryptyr |
| Abbvie INC. | $222.60 | 2024-2025 | |
| Harrow Eye, LLC | $218.93 | 2024-2025 | Vevye |
| Sight Sciences, INC. | $159.22 | 2025 | Tearcare System, Omni Surgical System |
| Sun Pharmaceutical Industries INC. | $139.42 | 2021-2025 | |
| Dompe US, INC. | $59.07 | 2025 | Oxervate |
| Tearlab Corp | $18.83 | 2024 | Scoutpro Osmolarity System |
| Apellis Pharmaceuticals, INC. | $16.56 | 2025 | Syfovre |
| Johnson & Johnson Surgical Vision, INC. | $13.90 | 2023 | Tecnis Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devyn Glover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.